Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy

被引：0
|
作者：
Yanwen Yao
Dongmei Yuan
Hongbing Liu
Xiaoling Gu
Yong Song
机构：
[1] Jinling Hospital,Department of Respiratory Medicine
[2] Nanjing University School of Medicine,undefined
来源：
Cancer Immunology, Immunotherapy | 2013年 / 62卷
关键词：
Neutrophil to lymphocyte ratio; Prognostic factor; Tumor-related inflammation; Non-small cell lung cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：471 / 479
页数：8
相关论文
共 50 条
  • [31] Prognostic model in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy
    Radosavljevic, D. Z.
    Gavrilovic, D.
    Golubicic, I.
    Jelic, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy
    Miao, Yi
    Yan, Qin
    Li, Shuangdi
    Li, Bilan
    Feng, Youji
    CANCER BIOMARKERS, 2016, 17 (01) : 33 - 40
  • [33] Cardiotoxicity in advanced non-small cell lung cancer patients treated with platinum and non-platinum based combinations as first-line treatment
    Wachters, FM
    Van Der Graaf, WTA
    Groen, HJM
    ANTICANCER RESEARCH, 2004, 24 (3B) : 2079 - 2083
  • [34] Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy
    Vassalou, Helen
    Stathopoulos, Efstathios
    Fiolitaki, Georgia
    Koutsopoulos, Anastasios
    Voutsina, Alexandra
    Georgoulias, Vassilis
    Mavroudis, Dimitris
    LUNG CANCER, 2013, 82 (02) : 324 - 329
  • [35] PROGNOSTIC IMPORTANCE OF RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Radosavljevic, D.
    Kezic, I.
    Jelic, S.
    Golubicic, I.
    ANNALS OF ONCOLOGY, 2008, 19 : 111 - 111
  • [36] Response to first-line chemotherapy of docetaxel combined with platinum predicting the prognosis and subsequent treatment of patients with non-small cell lung cancer
    Liu, Hongbing
    Wu, Ying
    Wang, Zhaofeng
    Song, Yong
    THORACIC CANCER, 2014, 5 (04) : 337 - 342
  • [37] Genetic variants as predictors of toxicity and response in patients with non-small cell lung cancer undergoing first-line platinum-based chemotherapy: Design of the multicenterPGxLUNGstudy
    de Jong, Corine
    Herder, Gerarda J. M.
    Deneer, Vera H. M.
    THORACIC CANCER, 2020, 11 (12) : 3634 - 3640
  • [38] Blood T cell diversity associated with the prognosis of advanced non-small cell lung carcinoma treated with first-line pemetrexed based chemotherapy
    Qian, Li
    Zhaohui, Zhang
    Yaping, Xu
    Zhentian, Liu
    Zhentao, Liu
    Qiqi, Wang
    Yangchun, Gu
    Yan'e, Liu
    Wencheng, Yin
    Fumei, Yi
    Yanhong, Yao
    Baoshan, Cao
    Li, Liang
    THORACIC CANCER, 2021, 12 (07) : 997 - 1005
  • [39] KRAS Mutations in Advanced Nonsquamous Non-Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value
    Mellema, Wouter W.
    Dingemans, Anne-Marie C.
    Thunnissen, Erik
    Snijders, Peter J. F.
    Derks, Jules
    Heideman, Danielle A. M.
    Van Suylen, Robertjan
    Smit, Egbert F.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (09) : 1190 - 1195
  • [40] Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy
    Papadaki, Chara
    Monastirioti, Alexia
    Rounis, Konstantinos
    Makrakis, Dimitrios
    Kalbakis, Konstantinos
    Nikolaou, Christoforos
    Mavroudis, Dimitrios
    Agelaki, Sofia
    CANCERS, 2020, 12 (05)
12345